GSK 189074 | SGLT2抑制剂
Remogliflozin
GSK 189074
CAS 329045-45-6
C23H34N2O7 MW 450.53
Purity: 99%
|
Biological Activity:
Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Its prodrug is Remoglifozin etabonate (GSK 189075), investigated as a treatment of anti diabetes type II.
References: Y Fujimori et al. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. J. Pharmacol. Exp. Ther. 2008, 327(1), 268-276.
Chemical Name: (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yloxy)tetrahydro-2H-pyran-3,4,5-triol
|
| Remogliflozin | SGLT2 inhibitor | Axon Medchem | Axon 1634 | GSK 189074 |
| 单位名称: |
|
详细地址:
北京市海淀区澄湾街19号院大北农凤凰国际创新园5号楼
|
|
qq:
2477120690
|
| 联系电话: |
| Email: |